




Fulvestrant is a selective estrogen receptor (ER) down-
regulator; fulvestrant inhibits ER dimerization [1] and reduces
ER’s half-life [2]. In preclinical models, fulvestrant inhibited
cell growth of the DU145 prostate cancer (PCa) cell line
through an ER-b-dependent mechanism [3]. Metastatic PCa
expresses ER-b mainly in metastases to the lymph nodes and
bones [4].
Androgen receptor (AR) expression is retained in
a significant proportion of castration-resistant prostate cancer
(CRPC) [5]. Bhattacharyya treated PCa cell lines with
fulvestrant obtaining a 70% of inhibition of the cell growth,
demonstrating that fulvestrant is a potent AR down-regulator
[6]; thus, combined down-regulation of ARs and ERs appears
as an attractive strategy for treating CRPC.
materials and methods
From June 2008 to January 2009, seven performance status (PS) of
zero to two on the ECOG scale (PS 0, one patient; PS 2, four
patients; PS 2, two patients) CRPC patients, evidenced by
a progressively rising prostate-specific antigen (PSA) or an
increase in tumor mass on bone scan, X-ray, computed
tomography scan or magnetic resonance imaging despite
a castrate level of testosterone (testosterone <20 ng/dl) when they
received the first line of chemotherapy, were treated with 500 mg
of fulvestrant i.m. every 14 days for the first month and 250 mg
monthly thereafter. Neither the number of previous hormonal
therapies nor the number of chemotherapy treatments was
limited. Patients had a mean age of 74 years (range 54–83 years).
All patients had received two to four lines of prior hormone
therapy (mean 3.14). Five patients had received at least one
chemotherapy line; the number of chemotherapy lines varied
from 1 to 3 (mean 1.80). One patient had received oral sunitinib.
All patients had detectable PSA levels at the start of fulvestrant.
Annals of Oncology letters to the editor
Volume 21 |No. 5 |May 2010 letters to the editor | 1131







The patients presented with a median baseline PSA of 189 ng/ml
(range 21.9–2462 ng/ml) before the first treatment.
results
A total of 55 injections of fulvestrant were administered. The
mean number of administrations was 7.83 (7–9). Grade 2
asthenia in one patient was the only recorded side-effect in our
cohort.
In six of the seven treated patients, a PSA level reduction was
recorded. The maximum PSA decrease observed ranged from
40% to 99% (median 60%). PSA response was established in
five of these six patients. The median observed duration of PSA
response was 1.50 months (range 0.27–2.67 months) (Figure 1).
One patient refused treatment continuation despite PSA
control and was lost to follow-up.
discussion
The role of additional hormonal manipulations in CRPC
patients progressing on cytotoxic chemotherapy has not been
well defined. Recently, interesting data have been provided with
the use of abiraterone acetate [7], ketoconazole [8], and
diethylstilbestrol [9], supporting the hypotheses of the existence
of some degree of androgen dependence in the context of
CRPC that can be exploited to treat this disease.
In our case, we analyzed the responses to fulvestrant acetate
in seven highly pretreated CRPC patients. We observed a mean
PSA decrease of 68.3% in patients who responded. No relevant
side-effect was recorded.
Our results differ, and compare favorably, with the trial of
Chadha et al. [10] where no PSA response was obtained.However,
Chadha didn’t use a loading-dose schedule. In our cohort, the PSA
began to rise soon after the fulvestrant dose was reduced to
monthly 250 mg; so, under our point of view, the existence of
a phenomenon of dose response for fulvestrant in Pca should be
considered. On the basis of our results, we propose additional
investigations of fulvestrant in patients with CRPC as well as the
inclusion of fulvestrant in future trials of PCa.
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Figure 1. Prostate-specific antigen (PSA) level evolution in the group of
responding patients.
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